

CORRESPONDENCE

Hydroxychloroquine in Hospitalized Patients with Covid-19

TO THE EDITOR: We were surprised by the hydroxychloroquine dose chosen in the Randomized Evaluation of Covid-19 Therapy (RECOVERY) trial conducted by Horby et al. (Nov. 19 issue).¹ In this trial, patients received a higher dose of hydroxychloroquine (4 g cumulated over the first 3 days) than that administered in the trial conducted by Lagier et al.² (600 mg per day), and it was similar to that in the trial conducted by Borba et al.³

In vitro studies show that the effect of hydroxychloroquine is mainly mediated by alkalization of the phagolysosomes,⁴ where it can concentrate about 1500 times more than in plasma. This effect can be obtained with low doses of hydroxychloroquine because of its long elimination half-life. High doses may therefore be useless or even deleterious because of the anti-interferon action of hydroxychloroquine,⁵ which may result in a more severe form of Covid-19.⁶ The dose used in the RECOVERY trial, the second highest after that in the trial conducted by Borba et al., arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.

Alexis Lacout, M.D.

Surgical Medical Center of Tronquieres–Elsan
Aurillac, France

Christian Perronne, M.D., Ph.D.

Versailles Saint-Quentin-en-Yvelines University
Garches, France

Valere Lounnas, Ph.D.

European Molecular Biology Laboratory
Heidelberg, Germany

No potential conflict of interest relevant to this letter was reported.

This letter was published on February 10, 2021, at NEJM.org.

1. The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. *N Engl J Med* 2020;383:2030-40.

2. Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. *Travel Med Infect Dis* 2020;36:101791.

3. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. *JAMA Netw Open* 2020;3(4):e208857.

4. Morrisette T, Lodise TP, Scheetz MH, Goswami S, Pogue JM, Rybak MJ. The pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for COVID-19: putting the cart before the horse. *Infect Dis Ther* 2020;9:561-72.

5. Gies V, Bekaddour N, Dieudonné Y, et al. Beyond anti-viral effects of chloroquine/hydroxychloroquine. *Front Immunol* 2020;11:1409.

6. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 2020;369:718-24.

DOI: 10.1056/NEJMc2035374

THE AUTHORS REPLY: Hydroxychloroquine was evaluated in the RECOVERY trial primarily as an antiviral drug. Hydroxychloroquine and chloroquine show only modest antiviral activity in cell-culture systems. The dosing schedule of hydroxychloroquine in the RECOVERY trial was therefore designed to provide the highest tissue concentrations that were safe in order to provide the maximum antiviral activity and thus the best chance of therapeutic benefit.¹ These doses were based on pharmacokinetic modeling in malaria and rheumatologic conditions and were informed by safety thresholds determined from toxicokinetic data on intentional overdoses with the closely related chloroquine.²

The base equivalent maintenance doses studied in the RECOVERY and World Health Organization (WHO) Solidarity trials³ are approximately half those evaluated in the study of chloroquine by Borba et al.⁴ Whereas the dosing schedule in the trial conducted by Borba et al. was predicted to confer an increased risk of toxicity,² the dosing schedule in the RECOVERY and WHO Solidarity trials was not. There was no evidence of cardiovascular toxicity in either trial. We know of no evidence that the anti-interferon activity of hydroxychloroquine would affect disease progression in hospitalized patients.

Peter Horby, F.R.C.P.

Nicholas J. White, F.R.S.

Martin J. Landray, F.R.C.P.

University of Oxford
Oxford, United Kingdom
recoverytrial@ndph.ox.ac.uk

Since publication of their article, Drs. Horby and Landray report receiving donated supplies of the REGN-COV2 monoclonal

antibody cocktail for use in the RECOVERY trial from Regeneron Pharmaceuticals. No further potential conflict of interest relevant to this letter was reported.

This letter was published on February 10, 2021, at NEJM.org.

1. White NJ, Watson JA, Høglund RM, Chan XHS, Cheah PY, Tarning J. COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. *PLoS Med* 2020;17(9):e1003252.
2. Watson JA, Tarning J, Høglund RM, et al. Concentration-

dependent mortality of chloroquine in overdose. *Elife* 2020;9:e58631 .

3. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — interim WHO Solidarity trial results. *N Engl J Med*. DOI: 10.1056/NEJMoa2023184.

4. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. *JAMA Netw Open* 2020;3(4):e208857.

DOI: 10.1056/NEJMc2035374

Correspondence Copyright © 2021 Massachusetts Medical Society.